Outbreak update, checked 27 October 2026. The World Health Organization (WHO) published a Disease Outbreak News report on 23 October 2026 about Bundibugyo virus disease (BVD), a form of Ebola disease, affecting the Democratic Republic of the Congo (DRC) with imported cases in Kenya and Nigeria. WHO’s daily surveillance table updated through 24 October contains newer figures than its 23 October bulletin. The dates must not be mixed.
What the official WHO figures show
| Location | Confirmed cases | Confirmed deaths | Data cutoff |
|---|---|---|---|
| Democratic Republic of the Congo | 9,964 | 4,841 | 24 October 2026 |
| Kenya | 9 | 2 | 23 October 2026 |
| Nigeria | 1 | Not reported in the WHO table | 24 October 2026 |
The DRC confirmed-case fatality proportion in the WHO table is approximately 49%. The earlier 23 October WHO bulletin reported 9,704 confirmed cases and 4,687 deaths in the DRC as of 20 October; these are earlier cutoff figures, not an alternative count to add to the later total. These figures do not represent cases in India. WHO’s surveillance numbers are subject to retrospective revision.
What is Bundibugyo virus disease?
BVD is an Ebola disease caused by Bundibugyo virus. Transmission is linked to direct contact with infected blood, body fluids or contaminated materials and unsafe burial practices; healthcare-associated transmission is a major concern when infection prevention and control (IPC) is inadequate. The incubation period is generally 2–21 days; people are not considered infectious before symptom onset. Early symptoms such as fever, fatigue, headache and muscle pain are nonspecific. Exposure history and appropriate laboratory testing are essential for diagnosis.
Healthcare facility preparedness
- Recognise risk by exposure: compatible symptoms plus relevant travel or contact history should trigger an immediate infection-control and public-health consultation.
- Isolate and refer safely: follow national/state reporting, isolation and designated referral pathways; do not improvise patient transport.
- Protect staff: apply standard and transmission-based precautions, correct PPE selection and supervised donning/doffing where required.
- Coordinate specimens: suspected Ebola samples require authorised laboratory and public-health coordination; do not send routine samples without advance notification.
- Communicate accurately: avoid claiming local circulation without an official Indian advisory or confirmed data.
Vaccine trial does not equal approved vaccine
WHO reported the launch of the TUMAINI Phase 2/3 trial on 23 October 2026 evaluating candidate vaccines against Bundibugyo virus. This is a clinical research milestone, not a licensed vaccine programme. At the WHO report date there was no approved BVD-specific vaccine or treatment; supportive clinical care, rapid case identification, contact follow-up and infection control remain critical.
Global and India relevance
WHO assessed global risk as low in its previous rapid risk assessment while reassessing the evolving outbreak. It did not recommend general travel or trade restrictions on affected countries. For Indian hospitals, the appropriate takeaway is travel/exposure-based preparedness and adherence to MoHFW/NCDC advisories—not alarm or a claim of an outbreak in India.
Official WHO references
- WHO Disease Outbreak News: Bundibugyo virus disease (23 October 2026)
- WHO Alert and Response: daily epidemiological table, DRC data as of 24 October 2026
Surveillance update, not individual clinical advice. Data cutoffs differ by country and may change; suspected cases require immediate public-health coordination.